Specialty Chemicals company Balaji Amines announced Q3FY26 results Revenue: Rs 33,130.1 lakh against Rs 31,272.84 lakh during Q3FY25, change 6%. PBT: Rs 4,598.76 lakh against Rs 4,089.24 lakh during Q3FY25, change 12%. PAT: Rs 3,075.69 lakh against Rs 3,113.89 lakh during Q3FY25, change -1%. EPS: 9.49 for Q3FY26. Result PDF
Specialty Chemicals company Balaji Amines announced Q1FY26 results Revenue from Operations for Q1FY26 stood at Rs 367 crore, as compared to Rs 361 crore in Q4FY25 keeping the performance track intact though the volume growth is seen. The stable commodity prices have allowed us to have the track of performance. Total volumes stood at 27,570 MT for Q1FY26 as against 25,871 MT in Q4FY25. For Q1FY26 Amines volumes stood at 7,573 MT. Amines Derivatives volumes stood at 8,108 MT. Specialty Chemicals volumes stood at 11,889 MT. EBITDA for Q1FY26 was Rs 64 crore, as compared to Rs 68 crore in Q4FY25 and Rs 74 crore in Q1FY25. EBITDA margin for Q1FY26 stood at 17% as against 19% in Q4FY25 and 19% in Q1FY25. PAT for Q1FY26 was Rs 37 crore as compared to Rs 40 crore in Q4FY25. Diluted EPS for Q1FY26 stood at Rs 11.73 per equity share as against Rs 12.36 in Q4FY25. D. Ram Reddy, Managing Director, said: “During Q1FY26, our financial and business performance remained stable, supported by a disciplined working model with stable commodity prices. As volume uptake gradually improves , we anticipate EBITDA and PAT margins to expand, in line with the industry recovery. With the present global and domestic scenario, the utilization of expanded capacities may be impacted in the coming quarters until the basic contribution for our products come through. At BAL, we remain focused on driving sustainable progress, backed by ongoing investments in key projects and our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade are yet to yield better volumes in serving the domestic market as we have a better product to offer at a competitive pricing, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a stable outlook for short term opportunities, anticipating growth and increased market driven balanced approach for medium to long term with better prospects. As our inherent strengths and competencies position us as a leading force in Amines and Specialty Chemicals, helping us navigate market dynamics and advance towards greater excellence.” Result PDF
Specialty Chemicals company Balaji Amines announced Q4FY25 & FY25 results Consolidated Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 stood at Rs 361 crore, as compared to Rs 321 crore in Q3FY25 Total volumes stood at 25,871 MT for Q4FY25 as against 24,107 MT in Q3FY25. EBITDA for Q4FY25 was Rs 68 crore, as compared to Rs 54 crore in Q3FY25 and Rs 106 crore in Q4FY24. EBITDA margin for Q4FY25 stood at 19% as against 17% in Q3FY25 and 25% in Q4FY24. PAT for Q4FY25 was Rs 40 crore as compared to Rs 31 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.36 per equity share as against Rs 10.24 in Q3FY25. Consolidated FY25 Financial Highlights: Total Income decreased by 14.4%, from Rs 1,671 crore to Rs 1,430 crore. EBITDA declined by 24.9%, from Rs 353 crore to Rs 265 crore. EBITDA Margin fell by 200 bps, from 21% to 19%. PAT dropped by 31.5%, from Rs 232 crore to Rs 159 crore. Sales Volume declined by 4.5%, from 1,09,320 MT to 1,04,393 MT. Cash PAT decreased by 27.5%, from Rs 284 crore to Rs 206 crore. Standalone Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 stood at Rs 327 crore, as compared to Rs 305 crore in Q3FY25 Total volumes stood at 24,047 MT for Q4FY25 as against 23,447 MT in Q3FY25. EBITDA for Q4FY25 was Rs 64 crore, as compared to Rs 57 crore in Q3FY25 and Rs 95 crore in Q4FY24 EBITDA margin for Q4FY25 stood at 20% as against 19% in Q3FY25 and 25% in Q4FY24. PAT for Q4FY25 was Rs 40 crore as compared to Rs 36 crore in Q3FY25. Diluted EPS for Q4FY25 stood at Rs 12.22 per equity share as against Rs 11.01 in Q3FY25. Standalone FY25 Financial Highlights: Total Income decreased by 4.6%, from Rs 1,359 crore to Rs 1,296 crore. EBITDA declined by 6.7%, from Rs 267 crore to Rs 249 crore. EBITDA Margin reduced by 100 bps, from 20% to 19%. PAT decreased by 8.8%, from Rs 171 crore to Rs 156 crore. Cash PAT dropped by 4.2%, from Rs 213 crore to Rs 204 crore. Sales Volume increased by 1.5%, from 96,596 MT to 98,086 MT. On the performance, D. Ram Reddy, Managing Director, commented, “During Q4FY25, our business performance showed improvement compared to the rest of the financial year, supported by favorable global macroeconomic conditions. As volume uptake gradually increases, we expect EBITDA and PAT margins to improve in line with broader industry recovery trends. However, geopolitical tensions and tariff-related challenges across global markets may continue to impact growth across several sectors in which we operate. These factors have weighed on domestic demand, but we anticipate that better utilization of expanded capacities will support margin recovery in the coming quarters. Pharmaceutical sector demand remained steady, contributing to base volumes, while the agrochemical segment exhibited volatility during the quarter. We continue to make progress on our strategic capex initiatives, including Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether projects, which are moving forward as planned. On the sustainability front, we are pleased to announce that our 6 MW AC Solar Power Plant was commissioned on 2 nd April, 2025. The plant is being brought online in a phased manner under Grid Connectivity, and the power generated will be utilized for captive consumption. Looking ahead, we remain focused on enhancing operational efficiencies, managing input costs and expanding our product portfolio to deliver sustained value to all stakeholders.” Result PDF